Stuart Sharpless

Director/Designer at Decorus Furniture

[Topinfo @TopTradersADVFN]

Okay so the next Pharma to move next I think is #SVNS . This one was hot for months with multiple excellent news and it hit 0.39p highs recently and even at that price people were suggesting it’s worth much more than 0.39p and arguably it probably is. See all the good news it’s had these past few months and it had a recent placing at 0.30p and now is 0.27p so it’s cheap and 12% below the recent placing price. I think as a trade there is 30% in this. If looking at longer term then much more than 30% but from here 30% rise would put it around 0.35p so that’s the initial target I think. I think this target is conservative and achievable and I know @MylesMcNulty is a big fan of #SVNS and called it spot on from the lows. Now it’s time to bounce having consolidated lately. On positive news this will rise significantly again especially at the moment with the Pharma sector being so hot. As always please DYOR and don’t just buy because I say it’s going to rise but this is my opinion and this is one Pharma that is looking very undervalued at these prices. Tops #SVNS

[Serial Investor @SerialInvestor8]

Solvonis Therapeutics #SVNS

🚨 BREAKING NEWS! CEO just dropped two major catalysts in interview:

🔥 60% of NHS AUD specialists now involved in SVN-001.
🔥 Licensing talks underway with mid-tier pharmas.

This is THE setup for a massive re-rate!

https://t.co/XiHW8fRU5e

[Solvonis Therapeutics plc @Solvonis]

Congrats to @SolvonisTx Chair, Dennis Purcell, on landmark $1.9B @AbbVie–IGI deal

As a Board Director at IGI, he played a key role in one of biotech’s biggest licensing agrmnts of 2025

🔹$700M upfront 🔹$1.225B in milestones 🔹Tiered royalties
Proud to have him lead Solvonis

[Solvonis Therapeutics plc @Solvonis]

@SolvonisTx Chair Purcell joins Levin & Papadopoulos for a Lucid Capital Mrkts exclusive

Three of biotechs most influential voices

Must-watch conversation

📅 July 17 | 2PM ET 🎙️ Hosted by Elemér Piros
Proud to have Dennis lead Solvonis

#SVNS #Biotech #AIinBiotech #CNS

[Tom Winnifrith @TomWinnifrith]

Fancy 789% upside on a penny share? https://t.co/PFZAzV6zfF

[Stuart Sharpless @StuSharpless]

https://t.co/AMLuB4j3vQ

[Serial Investor @SerialInvestor8]

Solvonis Therapeutics #SVNS

The next Ozempic?

[Serial Investor @SerialInvestor8]

Solvonis Therapeutics #SVNS

A once-in-a-generation steal.

[Myles McNulty @MylesMcNulty]

Five sessions on from the equity raise and #HEX is through 24p, +50% from the placing price already.

Momentum building, I think 30p could come much sooner than month-end.

The near-term prospect of $20m pre-tax cash flows versus the current mkt cap of $60m is clearly doing the job!

[Solvonis Therapeutics plc @Solvonis]

Based on these promising early results, Awakn will expand its aminoindane program to synthesize a further range of aminoindane compounds in collaboration with Concept Life Sciences. Learn more: https://t.co/A3g1Id9uyT $AWKN $AWKNF

[Myles McNulty @MylesMcNulty]

Graft Polymer #GPL has been climbing quietly under the radar the past three weeks, following the major pullback in the latter half of October. Now +50% since the lows.

Definitely a buyer or two around. Do they know something? Probably.

Eurofins study results due any day now, and I suspect new chairman Dennis Purcell has also been busy on new introductions and deals. As previously stated, I get the impression Dennis wants GPL as his preferred listed vehicle focusing on mental disorders. A mammoth new frontier in biotech. Graft Polymer’s existing technology is just the start for the Group.

[Myles McNulty @MylesMcNulty]

Major announcement from nano-cap biotech, Graft Polymer #GPL, which focuses on metal health disorders:

Appointment of biotechnology industry leader Dennis Purcell as Chairman

Phenomenal credentials for a guy joining a £3m mkt cap business - but he gives his rationale for joining in the interview ⬇️

Market is now belatedly realizing the significance of appointment for GPL...

[Myles McNulty @MylesMcNulty]

A very quick turnaround anticipated for this pre-clinical study being carried out by Eurofins on behalf of #GPL - possibly as fast as two weeks.

"The focus of this joint programme (with Awakn) is the development of next-generation medicines targeting trauma-related mental health conditions, such as Post-Traumatic Stress Disorder ("PTSD"), a condition affecting approximately 13 million adults in the U.S. and 20 million individuals across the US, UK, and key European markets.

The aminoindane series being developed shows great promise in modulating key neurotransmitter systems involved in mental health conditions like PTSD. By targeting serotonin, dopamine, and noradrenaline reuptake, this pharmacological testing could unlock new therapeutic pathways for addressing trauma-related disorders."

True frontier stuff. Just a tad punchy, on the R/R scales...!

In the meantime, expecting new chairman Dennis Purcell to swiftly open doors to further collaborations and investment.

For me, a momentum play in its nascent stages. Tiny mkt cap (£4m at 0.18p), cashed up, and new mgmt and shareholders with big ideas to grow this vehicle.

Not for the faint-hearted.

[Solvonis Therapeutics plc @Solvonis]

$AWKN provided an update on the progress of its pre-clinical program being executed as part of a collab. with @GraftPolymerPlc, that focuses on developing a new class of therapeutics for the potential treatment of #mentalhealth disorders, such as #PTSD. https://t.co/QQvJGSzqJe

[Solvonis Therapeutics plc @SolvonisTx]

With £400m investment in clinical trials and cutting-edge treatments, the UK cements its position as a global leader in life sciences. Congratulations to our partner @awakn_ls on appointing UK Leader @charnwooddisc to further advance drug discovery.

https://t.co/GiZL9I0NRI

[Solvonis Therapeutics plc @Solvonis]

The patent portfolio is now progressing well across multiple jurisdictions including the U.S., Europe and Canada. Learn more about our patent status and IP protection progress to date: https://t.co/SeTdRblpaS $AWKN $AWKNF

[Zephyr Energy @ZephyrEnergyPlc]

We are pleased to announce that following a detailed selection process, #ZPHR has signed a rig contract with Helmerich & Payne (H&P) for its Rig 257 which will be used to redrill the State 36-2 well (State 36-2R) in the Paradox Basin.

Announcement: https://t.co/oeYdb7VI6M

[Zephyr Energy @ZephyrEnergyPlc]

The University of Utah’s Energy & Geosciences Institute (“EGI") remains one of #ZPHR's most valued and trusted partners. While Zephyr’s team continues to plan the redrill of the State 36-2, EGI recently deployed its own team to install a passive seismic array at Zephyr’s...

[CleanTech Lithium @ctlithium]

📢 Final components of our #DLE Pilot Plant have arrived onsite and technicians from @sunresin are scheduled to join us at the end of Nov for the final testing and commissioning phase.

👉Read more here: https://t.co/fiCQmdkapY

$CTL $CTLHF #lithium

[Zephyr Energy @ZephyrEnergyPlc]

📹Our CEO, Colin Harrington is out at the 36-2 well in the Paradox Basin where we are completing the necessary well work prior to the forthcoming production test on the well.

#ZPHR